Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
- Conditions
- Liver CirrhosisVirusesHepatitis, Viral, HumanHepatitis C InfectionHepatocellular Carcinoma
- Interventions
- Biological: Civacir® 10%
- First Posted Date
- 2013-03-05
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Biotest Pharmaceuticals Corporation
- Target Recruit Count
- 80
- Registration Number
- NCT01804829
- Locations
- 🇺🇸
Florida Hospital Transplant Institute, Orlando, Florida, United States
🇺🇸Columbia University College of Physicians and Surgeons, New York, New York, United States
🇺🇸Ochsner Medical Center, New Orleans, Louisiana, United States
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: BT062 , intravenous administration
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Biotest Pharmaceuticals Corporation
- Target Recruit Count
- 64
- Registration Number
- NCT01638936
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
🇺🇸City of Hope, Duarte, California, United States
Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation
- Conditions
- Hepatitis B Virus Associated Liver Disease
- First Posted Date
- 2011-08-22
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Biotest Pharmaceuticals Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT01421212
- Locations
- 🇺🇸
Rush-Presbyterian - St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Mount Sinai Medical Center, New York, New York, United States
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2009-10-26
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Biotest Pharmaceuticals Corporation
- Target Recruit Count
- 35
- Registration Number
- NCT01001442
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation
- Conditions
- Hepatitis B, Chronic
- Interventions
- Biological: Nabi-HB
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Biotest Pharmaceuticals Corporation
- Registration Number
- NCT00800787
Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2008-07-28
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Biotest Pharmaceuticals Corporation
- Target Recruit Count
- 32
- Registration Number
- NCT00723359
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Mount Sinai Medical Center, New York, New York, United States